Alghadeer Sultan, Mubarak Abdullah M, Alsuwayni Bashayr, Almurdhi Faisal, Almalki Hazim, Alotaibi Metib
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Department of Basic Sciences, PSCEMS, King Saud University, Riyadh, Saudi Arabia.
Saudi Pharm J. 2024 Oct;32(10):102168. doi: 10.1016/j.jsps.2024.102168. Epub 2024 Sep 4.
Despite the availability of new cardio-protective oral hypoglycemic drugs, insulin is often recommended as an add-on therapy for type-2 diabetes with hemoglobin A1C (HbA1C) ≥ 9. Introducing insulin as a choice for patients with uncontrolled hyperglycemia (HbA1C≥9) has been questionably associated with cardiovascular sequelae. This study aims to examine the association between insulin use and cardiovascular effects in type-2 diabetic patients with uncontrolled hyperglycemia.
A retrospective observational cohort study was conducted to identify cardiovascular complications between the two groups (patients with HbA1C≥9% on insulin versus those with HbA1C≥9% without insulin) at King Saud University Medical City (KSUMC). Patients with type-2 diabetes whose HbA1C was ≥ 9 during the period from 2015 to 2018 and who were followed up within the hospital for at least 5 years until the end of 2022 were included in the study.
A total of 366 patients were included in the study; 286 patients were on insulin, while 80 patients were not. The median baseline HbA1C levels were comparable between the two groups (10.2 versus 9.8). After 5 years of follow-up, there was no significant difference between the groups (29.4 % of insulin users versus 18.8 % of non-insulin users; p = 0.065). However, the incidence of other diabetes complications, such as retinopathy, nephropathy, and neuropathy, was significantly higher among patients who were on insulin compared to those not on insulin (50.7 % versus 27.5 %; p = 0.005). Additionally, the average of the last three HbA1C readings and the overall average HbA1C readings were significantly higher among patients who were on insulin (9.67 % versus 9.07 %; p = 0.001) compared to those not on insulin (9.64 % versus 9.11 %; p = 0.005).
Our study did not find a significant association between the use of insulin and cardiovascular complications. The association between insulin therapy and the development of other diabetes complications warrants further investigation.
尽管有新型心脏保护作用的口服降糖药,但对于糖化血红蛋白(HbA1C)≥9%的2型糖尿病患者,胰岛素常被推荐作为附加治疗药物。对于血糖控制不佳(HbA1C≥9%)的患者,选用胰岛素治疗是否会引发心血管后遗症仍存在疑问。本研究旨在探讨血糖控制不佳的2型糖尿病患者使用胰岛素与心血管效应之间的关联。
在沙特国王大学医学城(KSUMC)开展了一项回顾性观察队列研究,以确定两组患者(HbA1C≥9%且使用胰岛素的患者与HbA1C≥9%但未使用胰岛素的患者)的心血管并发症情况。纳入研究的患者为2015年至2018年期间HbA1C≥9%的2型糖尿病患者,且在医院随访至少5年直至2022年底。
本研究共纳入366例患者;其中286例使用胰岛素,80例未使用胰岛素。两组患者的基线HbA1C中位数水平相当(分别为10.2和9.8)。随访5年后,两组之间无显著差异(使用胰岛素的患者为29.4%,未使用胰岛素的患者为18.8%;p = 0.065)。然而,与未使用胰岛素的患者相比,使用胰岛素的患者发生视网膜病变、肾病和神经病变等其他糖尿病并发症的发生率显著更高(分别为50.7%和27.5%;p = 0.005)。此外,与未使用胰岛素的患者相比,使用胰岛素的患者最近三次HbA1C读数的平均值以及HbA1C读数的总体平均值显著更高(分别为9.67%和9.07%;p = 0.001)(9.64%和9.11%;p = 0.005)。
我们的研究未发现使用胰岛素与心血管并发症之间存在显著关联。胰岛素治疗与其他糖尿病并发症发生之间的关联值得进一步研究。